The extension of the program followed an evaluation by the Swiss National Science Foundation (SNSF). The assessment of the NCCR AntiResist, a program marked by its innovative, multidisciplinary approach to antibiotic resistance research, yielded positive results. This NCCR is performing pioneering work in how to approach this problem and the collection and analysis of clinical samples, along with the tissue models developed with this knowledge to investigate antibacterial agents are unique.
The Research Council of the SNSF has approved the continuation of the NCCR AntiResist, and has increased the SNSF’s contributions by 20 percent compared to the first four-year phase. For the second phase, which will run from August 2024 to July 2028, the NCCR will receive CHF 20.4 million from the SNSF. As part of its commitment to cutting-edge research, the University of Basel has decided, in step with the SNSF, to increase its financial support by one-fifth to CHF 4.8 million.
The NCCR AntiResist started its work in 2020. The program focuses on discovering new antibiotics and developing alternative strategies to combat antibiotic-resistant germs by directly linking basic research with clinical research.
Contact: Communications